Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry J Allen

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Cancer Biology & Therapy|April 2, 2009
Mutagenesis induced by targeted alpha therapy using 213Bi-cDTPA-9.2.27 in lacZ transgenic miceBarry J Allen, Trina So, Syed M Abbas Rizvi, et al.
Immunotherapy|September 15, 2011
Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanomaBarry J Allen, Apresh A Singla, Syed M Abbas Rizvi, et al.
Contrast Media & Molecular Imaging|October 21, 2014
Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivoSaeed Shanehsazzadeh, Cordula Gruettner, Afsaneh Lahooti, et al.
Contrast Media & Molecular Imaging|January 3, 2013
Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancerMohammad Abdolahi, Daryoush Shahbazi-Gahrouei, Sophie Laurent, et al.
Cancer Letters|March 24, 2004
Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugateYong Li, Paul J Cozzi, Chang F Qu, et al.
Nuclear Medicine Communications|July 30, 2013
Estimated background doses of [67Ga]-DTPA-USPIO in normal Balb/c mice as a potential therapeutic agent for liver and spleen cancersSaeed Shanehsazzadeh, Mohammad A Oghabian, Afsaneh Lahooti, et al.
Cancer Biology & Therapy|December 3, 2005
Intralesional targeted alpha therapy for metastatic melanomaBarry J Allen, Chand Raja, Syed Rizvi, et al.
Cancer Biology & Therapy|June 22, 2007
Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in preclinical targeted alpha therapy for cancerEmma Y Song, Syed M Abbas Rizvi, Chang F Qu, et al.
Cancer Biology & Therapy|April 1, 2006
Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft modelSyed M Abbas Rizvi, Yong Li, Emma Yan Jun Song, et al.
Clinical & Experimental Metastasis|February 14, 2006
Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancerChang F Qu, Emma Y Song, Yong Li, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Cancer Biology & Therapy|April 2, 2009
Mutagenesis induced by targeted alpha therapy using 213Bi-cDTPA-9.2.27 in lacZ transgenic miceBarry J Allen, Trina So, Syed M Abbas Rizvi, et al.
Immunotherapy|September 15, 2011
Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanomaBarry J Allen, Apresh A Singla, Syed M Abbas Rizvi, et al.
Contrast Media & Molecular Imaging|October 21, 2014
Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivoSaeed Shanehsazzadeh, Cordula Gruettner, Afsaneh Lahooti, et al.
Contrast Media & Molecular Imaging|January 3, 2013
Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancerMohammad Abdolahi, Daryoush Shahbazi-Gahrouei, Sophie Laurent, et al.
Cancer Letters|March 24, 2004
Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugateYong Li, Paul J Cozzi, Chang F Qu, et al.
Nuclear Medicine Communications|July 30, 2013
Estimated background doses of [67Ga]-DTPA-USPIO in normal Balb/c mice as a potential therapeutic agent for liver and spleen cancersSaeed Shanehsazzadeh, Mohammad A Oghabian, Afsaneh Lahooti, et al.
Cancer Biology & Therapy|December 3, 2005
Intralesional targeted alpha therapy for metastatic melanomaBarry J Allen, Chand Raja, Syed Rizvi, et al.
Cancer Biology & Therapy|June 22, 2007
Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in preclinical targeted alpha therapy for cancerEmma Y Song, Syed M Abbas Rizvi, Chang F Qu, et al.
Cancer Biology & Therapy|April 1, 2006
Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft modelSyed M Abbas Rizvi, Yong Li, Emma Yan Jun Song, et al.
Clinical & Experimental Metastasis|February 14, 2006
Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancerChang F Qu, Emma Y Song, Yong Li, et al.
Pageof 6